Pharmaceuticals, Biotechnology and Life Sciences
Reported 27-patient dosimetry data from the lead-in cohort of the SPLASH trial Randomization phase of SPLASH trial ongoing, top line…
CHMP opinion based on Phase III REACH2 and REACH3 trials that showed Jakavi improved response rates and failure-free survival compared…
Positive opinion paves way for third indication in Europe for Kymriah, a potentially definitive single infusion CAR-T cell therapy treatment…
Tapinarof demonstrated continued improvements for up to 52 weeks in efficacy outcomes, quality of life measures, and tolerability scores with…
COPENHAGEN, Denmark, March 24, 2022 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative…
FORT COLLINS, Colo., March 24, 2022 (GLOBE NEWSWIRE) — Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a…
MENLO PARK, Calif., March 24, 2022 (GLOBE NEWSWIRE) — AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing treatments…
Continued Progress Towards Optimizing Clinical Development Plans On Track to Initiate Phase 2b Study of Omilancor in Ulcerative Colitis Later this…
Pipeline Advancement Continues with Ongoing Phase 2 Studies for Voriconazole and Tacrolimus Programs Partnership Activity Surrounding Thin Film Freezing Continues…
— Proposal of one-tier board structure & appointment of three new directors — Mechelen, Belgium; 24 March 2022, 21.01 CET;…